Linked Life Data

17192791

Source:http://linkedlifedata.com/resource/pubmed/id/17192791

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-3-15
pubmed:abstractText
Previously, we used the reverse transcription-polymerase chain reaction (RT-PCR) to show that mammaglobin (MGB1) can serve as a differential marker of breast cancer metastasis from primary lung cancer. However, mRNA-based methods are not appropriate for use in clinical practices. In this study, we examined MGB1 protein expression in 480 tumors from various organs using immunohistochemical detection and a tissue microarray technique. Breast cancers expressing MGB1 were also analyzed clinicopathologically to determine whether these cancers constitute a characteristic subset. Immunohistochemically, MGB1 was expressed specifically in breast cancers. Of the other cancers examined, including 29 of the head and neck, eight of the thyroid, 106 of the lung, 35 of the gastrointestinal tract, three of the pancreas, 14 of the uterine cervix and 13 of the ovary, none were positive for MGB1 except a proportion of salivary gland tumors (6/11, 55%) and endometrial cancers (3/23, 13%). Among the 238 breast cancers, MGB1 was expressed in 114 (48%), most of which were classified histologically as invasive duct or lobular carcinomas. Clinicopathologically, MGB1 expression was associated with positive expression of estrogen receptors and negative expression of CK5, but not with pathological stage, HER2 gene amplification or p53 immunoreactivity. Kaplan-Meier analysis revealed prolonged disease-free survival in patients with MGB1-positive breast cancers (log rank test, P=0.016), but the Cox proportional hazard model failed to confirm that MGB1 was an independent prognostic factor (hazard ratio 1.77, P=0.1755). In terms of practical diagnosis, MGB1 immunohistochemistry can serve as a differential marker of breast cancer metastasis from primary lung cancer for two reasons. Firstly, HER2-positive breast cancer frequently lacks estrogen receptor expression, but MGB1 is expressed in about half of this subtype. Secondly, as primary lung adenocarcinomas may express estrogen receptors, MGB1 expression provides further discrimination of the origin of breast cancers.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0893-3952
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
208-14
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:17192791-Adenocarcinoma, pubmed-meshheading:17192791-Breast Neoplasms, pubmed-meshheading:17192791-Cell Count, pubmed-meshheading:17192791-Diagnosis, Differential, pubmed-meshheading:17192791-Disease-Free Survival, pubmed-meshheading:17192791-Female, pubmed-meshheading:17192791-Humans, pubmed-meshheading:17192791-Immunoenzyme Techniques, pubmed-meshheading:17192791-Japan, pubmed-meshheading:17192791-Lung Neoplasms, pubmed-meshheading:17192791-Mammaglobin A, pubmed-meshheading:17192791-Neoplasm Proteins, pubmed-meshheading:17192791-Neoplasm Staging, pubmed-meshheading:17192791-Receptors, Estrogen, pubmed-meshheading:17192791-Survival Rate, pubmed-meshheading:17192791-Tissue Array Analysis, pubmed-meshheading:17192791-Tumor Markers, Biological, pubmed-meshheading:17192791-Uteroglobin
pubmed:year
2007
pubmed:articleTitle
Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers.
pubmed:affiliation
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Aichi, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't